特立帕肽在绝经后骨质疏松症治疗中的应用概况。
Profile of teriparatide in the management of postmenopausal osteoporosis.
机构信息
Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA;
出版信息
Int J Womens Health. 2010 Aug 9;2:37-44. doi: 10.2147/ijwh.s4919.
Abstract
One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
摘要
每两名绝经后女性中就有一名面临因骨质疏松而骨折的风险。幸运的是，越来越多的治疗方法正被应用于治疗这种疾病和预防骨折。在过去十年中，出现了一类新的合成代谢药物，为骨质疏松症的治疗带来了一个新概念：即建立新的更强壮的骨骼，而不仅仅是抑制骨转换。目前正在积累更多的证据来了解如何最好地利用这些新的药物，以及哪些患者最受益。本文将综述特立帕肽治疗绝经后骨质疏松症的有效性、风险、时机和临床应用。
相似文献
1
Profile of teriparatide in the management of postmenopausal osteoporosis.特立帕肽在绝经后骨质疏松症治疗中的应用概况。
Int J Womens Health. 2010 Aug 9;2:37-44. doi: 10.2147/ijwh.s4919.
2
Management of postmenopausal osteoporosis and the prevention of fractures.绝经后骨质疏松症的管理及骨折预防
Panminerva Med. 2014 Jun;56(2):115-31. Epub 2014 Jun 19.
3
Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?用于治疗骨质疏松症的合成代谢药物：它们在治疗中可能处于什么地位？
Treat Endocrinol. 2006;5(6):347-58. doi: 10.2165/00024677-200605060-00003.
4
Anabolic skeletal therapy for osteoporosis.骨质疏松症的合成代谢骨骼疗法。
Arq Bras Endocrinol Metabol. 2006 Aug;50(4):745-54. doi: 10.1590/s0004-27302006000400019.
5
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.阿仑膦酸盐、依替膦酸盐、利塞膦酸盐、雷洛昔芬和特立帕肽用于预防和治疗绝经后骨质疏松症的系统评价与经济学评估
Health Technol Assess. 2005 Jun;9(22):1-160. doi: 10.3310/hta9220.
6
Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS).研究描述和纳入多国观察性研究的人群的基线特征特立帕肽在绝经后骨质疏松症妇女：亚洲和拉丁美洲骨折观察研究（ALAFOS）。
Curr Med Res Opin. 2019 Jun;35(6):1041-1049. doi: 10.1080/03007995.2018.1552576. Epub 2019 Jan 3.
7
Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).在现实环境中接受特立帕肽治疗的绝经后骨质疏松症女性的基线特征：来自亚洲和拉丁美洲骨折观察研究（ALAFOS）的亚区域分析。
Adv Rheumatol. 2019 Nov 8;59(1):46. doi: 10.1186/s42358-019-0088-2.
8
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.绝经后骨质疏松症女性中骨合成代谢治疗的疗效比较：一项随机对照试验的系统评价和网络荟萃分析。
Maturitas. 2019 Nov;129:12-22. doi: 10.1016/j.maturitas.2019.08.003. Epub 2019 Aug 10.
9
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
10
ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.绝经后骨质疏松症每周使用特立帕肽治疗的合成代谢骨窗：一项试点研究。
Endocr Pract. 2017 Jun;23(6):657-661. doi: 10.4158/EP161394.OR. Epub 2017 Feb 22.
引用本文的文献
1
Bone targeted nano-drug and nano-delivery.骨靶向纳米药物和纳米递药系统。
Bone Res. 2024 Sep 4;12(1):51. doi: 10.1038/s41413-024-00356-2.
2
Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model.IL-17 细胞因子的功能阻断通过增强皮质骨缺损模型中 FOXO1 和 ATF4 的活性来促进骨愈合。
Osteoporos Int. 2017 Jul;28(7):2207-2220. doi: 10.1007/s00198-017-4012-5. Epub 2017 Mar 24.
3
Medicarpin, a Natural Pterocarpan, Heals Cortical Bone Defect by Activation of Notch and Wnt Canonical Signaling Pathways.美迪紫檀素，一种天然紫檀素，通过激活Notch和Wnt经典信号通路修复皮质骨缺损。
PLoS One. 2015 Dec 11;10(12):e0144541. doi: 10.1371/journal.pone.0144541. eCollection 2015.
4
Treatment of post-menopausal osteoporosis: beyond bisphosphonates.绝经后骨质疏松症的治疗：超越双膦酸盐类药物
J Endocrinol Invest. 2015 Jan;38(1):13-29. doi: 10.1007/s40618-014-0152-z. Epub 2014 Sep 7.
5
Muscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role?肌肉-骨骼与脂肪-骨骼在调节骨量中的相互作用：甲状旁腺激素和甲状旁腺激素相关蛋白发挥作用吗？
Endocrine. 2014 Nov;47(2):389-400. doi: 10.1007/s12020-014-0273-3. Epub 2014 May 7.
6
Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.特立帕肽依从性和持久性与医疗保险部分 D 受者临床和经济结局的关联：一项回顾性队列研究。
BMC Musculoskelet Disord. 2013 Jan 3;14:4. doi: 10.1186/1471-2474-14-4.
7
Osteoporotic fracture and parathyroid hormone.骨质疏松性骨折与甲状旁腺激素
World J Orthop. 2011 Aug 18;2(8):67-74. doi: 10.5312/wjo.v2.i8.67.
本文引用的文献
1
Clinical update on teriparatide.特立帕肽的临床进展
Curr Rheumatol Rep. 2009 Jul;11(3):169-76. doi: 10.1007/s11926-009-0023-3.
2
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.通过定量和定性影像学评估确定特立帕肽降低椎体骨折风险的效果
Curr Med Res Opin. 2009 Apr;25(4):921-8. doi: 10.1185/03007990902790993.
3
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate.在持续长期服用阿仑膦酸盐的患者中，首次使用特立帕肽治疗一年后再次使用特立帕肽进行治疗。
J Bone Miner Res. 2009 Jun;24(6):1110-5. doi: 10.1359/jbmr.081250.
4
Teriparatide: a review of its use in osteoporosis.特立帕肽：其在骨质疏松症治疗中的应用综述
Drugs. 2008;68(18):2709-37. doi: 10.2165/0003495-200868180-00012.
5
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).特立帕肽治疗后严重绝经后骨质疏松症的序贯治疗：随机对照的欧洲福善美研究（EUROFORS）的最终结果
J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215.
6
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.阿仑膦酸盐或利塞膦酸盐治疗后骨质疏松症女性对特立帕肽的早期反应性。
J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5.
7
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.既往抗吸收治疗对骨质疏松绝经后妇女接受两年特立帕肽治疗后骨密度反应的影响。
J Clin Endocrinol Metab. 2008 Mar;93(3):852-60. doi: 10.1210/jc.2007-0711. Epub 2007 Dec 26.
8
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.特立帕肽或阿仑膦酸钠用于糖皮质激素诱导的骨质疏松症
N Engl J Med. 2007 Nov 15;357(20):2028-39. doi: 10.1056/NEJMoa071408.
9
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.甲状旁腺激素（1-34）治疗一个月对人髂骨松质骨、骨内膜和骨膜表面骨形成的影响。
J Bone Miner Res. 2007 Apr;22(4):495-502. doi: 10.1359/jbmr.070104.
10
Osteosarcoma and teriparatide?骨肉瘤与特立帕肽？
J Bone Miner Res. 2007 Feb;22(2):334. doi: 10.1359/jbmr.061111.
Zotero 插件